ES2150503T3 - Combinacion de agentes antagonistas de progesterona y anti-estrogenos con efecto agonista parcial para la terapia por reemplazo de hormonas para mujeres peri- y post-menopausicas. - Google Patents

Combinacion de agentes antagonistas de progesterona y anti-estrogenos con efecto agonista parcial para la terapia por reemplazo de hormonas para mujeres peri- y post-menopausicas.

Info

Publication number
ES2150503T3
ES2150503T3 ES94929553T ES94929553T ES2150503T3 ES 2150503 T3 ES2150503 T3 ES 2150503T3 ES 94929553 T ES94929553 T ES 94929553T ES 94929553 T ES94929553 T ES 94929553T ES 2150503 T3 ES2150503 T3 ES 2150503T3
Authority
ES
Spain
Prior art keywords
progesterone
pct
partial agonistic
therapy
women
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94929553T
Other languages
English (en)
Inventor
Kristof Chwalisz
Klaus Stockemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2150503T3 publication Critical patent/ES2150503T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION DESCRIBE LA UTILIZACION DE AL MENOS UN COMPUESTO CON ACTIVIDAD ANTAGONISTA A LA PROGESTERONA (AP) Y AL MENOS UN COMPUESTO CON ACTIVIDAD ANTIESTROGENICA (AE), JUNTOS CON UN EFECTO PARCIAL AGONISTICO PARA LA OBTENCION DE MEDICAMENTOS EN LA TERAPIA DE SUSTITUCION DE HORMONAS (TSH) PARA MUJERES PERIY POSTMENOPAUSICAS. CUANDO AP Y AE SE UTILIZAN EN COMBINACION, LA ESTIMULACION DEL ENDOMETRIO QUE SE CAUSA POR EL EFECTO PARCIAL AGONISTICO DE AE UTILIZADO SOLO, SE INHIBE POR AP. SE PROPONE UN MEDICAMENTO DE ACUERDO CON LA INVENCION QUE PODRIA LLEVAR POR EJEMPLO ONAPRISTON (AP) Y TAMOXIFEN (AE).
ES94929553T 1993-10-17 1994-10-17 Combinacion de agentes antagonistas de progesterona y anti-estrogenos con efecto agonista parcial para la terapia por reemplazo de hormonas para mujeres peri- y post-menopausicas. Expired - Lifetime ES2150503T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4335876A DE4335876A1 (de) 1993-10-17 1993-10-17 Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen

Publications (1)

Publication Number Publication Date
ES2150503T3 true ES2150503T3 (es) 2000-12-01

Family

ID=6500646

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94929553T Expired - Lifetime ES2150503T3 (es) 1993-10-17 1994-10-17 Combinacion de agentes antagonistas de progesterona y anti-estrogenos con efecto agonista parcial para la terapia por reemplazo de hormonas para mujeres peri- y post-menopausicas.

Country Status (19)

Country Link
US (1) US5719136A (es)
EP (1) EP0723439B1 (es)
JP (1) JPH09503774A (es)
KR (1) KR100348116B1 (es)
CN (1) CN1128613C (es)
AT (1) ATE196251T1 (es)
AU (1) AU691839B2 (es)
CA (1) CA2174327C (es)
CZ (1) CZ285690B6 (es)
DE (2) DE4335876A1 (es)
DK (1) DK0723439T3 (es)
ES (1) ES2150503T3 (es)
GR (1) GR3035054T3 (es)
HU (1) HUT74430A (es)
NO (1) NO308584B1 (es)
NZ (1) NZ274510A (es)
PT (1) PT723439E (es)
SK (1) SK281312B6 (es)
WO (1) WO1995011013A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893121B1 (en) * 1997-06-27 2002-03-13 Akzo Nobel N.V. Oral liquid medicine solution
CA2331318A1 (en) * 1998-05-15 1999-11-25 James Harrison Pickar Compositions comprising 2-phenyl-indole compounds and estrogen formulations
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
RU2005101635A (ru) * 2002-06-25 2005-08-10 Уайт (Us) Применение производных тиооксиндола в терапии гормонозависимых состояний
CN1662206A (zh) * 2002-06-25 2005-08-31 惠氏公司 硫代－2－羟基吲哚衍生物在治疗皮肤病中的用途
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
CA2529852A1 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
US7247625B2 (en) * 2003-10-09 2007-07-24 Wyeth 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators
US7323455B2 (en) * 2004-03-24 2008-01-29 Wyeth 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
US7414142B2 (en) * 2005-09-19 2008-08-19 Wyeth 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators
US7319152B2 (en) * 2005-09-19 2008-01-15 Wyeth 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
US20070066628A1 (en) * 2005-09-19 2007-03-22 Wyeth 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators
CN101448490A (zh) * 2006-05-22 2009-06-03 霍尔莫斯医疗有限公司 治疗慢性非细菌性前列腺炎的选择性雌激素受体调节剂或者芳香酶抑制剂
US7652018B2 (en) * 2006-08-15 2010-01-26 Wyeth Llc Imidazolidin-2-one derivatives useful as PR modulators
US20080045560A1 (en) * 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
WO2008021338A2 (en) * 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
US7649007B2 (en) * 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
WO2008021337A1 (en) 2006-08-15 2008-02-21 Wyeth Oxazinan-2-one derivatives useful as pr modulators
TW200815428A (en) * 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
EP2121553B1 (en) * 2007-02-14 2012-06-27 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
WO2008112495A1 (en) * 2007-03-09 2008-09-18 Wyeth Synthesis and characterization of polymorph form iii of 4-(2,(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile
US20080306131A1 (en) * 2007-06-05 2008-12-11 Wyeth Progesterone receptor modulator and uses thereof
JP6174156B2 (ja) 2012-10-19 2017-08-02 フェルミオン オサケ ユキチュア オスペミフェンの製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.

Also Published As

Publication number Publication date
HUT74430A (en) 1996-12-30
NZ274510A (en) 2001-03-30
WO1995011013A3 (de) 1995-06-29
WO1995011013A2 (de) 1995-04-27
GR3035054T3 (en) 2001-03-30
DK0723439T3 (da) 2000-10-30
CZ111196A3 (en) 1996-08-14
KR960704535A (ko) 1996-10-09
CN1135176A (zh) 1996-11-06
CA2174327A1 (en) 1995-04-27
SK48496A3 (en) 1997-01-08
CA2174327C (en) 2007-05-22
PT723439E (pt) 2001-01-31
HU9600992D0 (en) 1996-06-28
EP0723439A1 (de) 1996-07-31
JPH09503774A (ja) 1997-04-15
ATE196251T1 (de) 2000-09-15
DE59409522D1 (de) 2000-10-19
KR100348116B1 (ko) 2002-11-25
NO961502D0 (no) 1996-04-16
EP0723439B1 (de) 2000-09-13
SK281312B6 (sk) 2001-02-12
NO308584B1 (no) 2000-10-02
US5719136A (en) 1998-02-17
CZ285690B6 (cs) 1999-10-13
AU691839B2 (en) 1998-05-28
AU7856494A (en) 1995-05-08
DE4335876A1 (de) 1995-04-20
CN1128613C (zh) 2003-11-26
NO961502L (no) 1996-06-14

Similar Documents

Publication Publication Date Title
ES2150503T3 (es) Combinacion de agentes antagonistas de progesterona y anti-estrogenos con efecto agonista parcial para la terapia por reemplazo de hormonas para mujeres peri- y post-menopausicas.
AR011114A1 (es) COMPOSICIoN FARMACÉUTICA LIBRE DE LACTOSA EN FORMA GRANULADA O EN MEZCLA PARA EL TRATAMIENTO DE DESoRDENES INDUCIDOS POR HISTAMINA.
AR035131A1 (es) Composiciones topicas y metodos para el tratamiento del dolor
BR0114410A (pt) Associação de um antagonista de receptor cb1 e de sibutramina, as composições farmacêuticas que os contêm e a respectiva utilização para o tratamento da obesidade
ES2182357T3 (es) Nueva utilizacion de budesonide y formoterol.
ES2107235T3 (es) Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina.
BR0010138A (pt) Moduladores de receptores de glucocorticóides
BR9509019A (pt) Processo para fabricar unidades de dosagem farmacêutica e comprimido isento de solventes orgânicos
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
ATE171873T1 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
Cohen et al. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
BR9910329A (pt) Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto
ES2172600T3 (es) Composicion farmaceutica que comprende lamotrigina.
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
NO306700B1 (no) Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister
HRP20060040A2 (en) PURE D-(17α)-13-ETHYL-17-HYDROXY-18,19-DINORPREGN-4-ENE-20-YNE-3-ONE-3E- AND -3Z-OXIME ISOMERS, AS WELL AS PROCESS FOR THE SYNTHESIS OF THE MIXTURE OF ISOMERS AND THE PURE ISOMERS
AR044450A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas
BR9911103A (pt) Antiestrógenos, processo para sua preparação e seu uso farmacêutico
Kirchhoff et al. Estrogen agonistic and antagonistic action of 8 non-steroidal antiestrogens on progestin receptor induction in rat pituitary gland and uterus
Mahendran et al. Contact leukoderma secondary to occupational toluenediamine sulfate exposure.
GR3024854T3 (en) Drugs for preventing the development of tolerance during treatment with benzodiazepine-receptor-binding substances.
PT1090028E (pt) 14,15-ciclopropano-androstanos insaturados processo para a sua preparacao e composicoes farmaceuticas que contem estes compostos
Heller Congenital bilateral hallux valgus
BE899277A (fr) Agents antimycotiques a haute liberation de substance active sous forme d'une solution et d'une pulverisation.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 723439

Country of ref document: ES